ImmuCell Q2 Growth
ImmuCell Reports 11.5% Sales Growth to $7.2M in Q2, Boosted by Domestic Demand
Anonymous
Key Points
1
Q2 2026 product-line performance shows Tri-Shield First Defense generating $4.9 million (up 8.3% year over year) and Dual-Force and other products at $2.3 million (up 19.1% year over year), with six-month totals of $12.8 million for Tri-Shield (up 25.1%) and $4.8 million for Dual-Force and other (up 10.9%).
2
Domestic and international split in the quarter and first half: Q2 domestic sales were $6.2 million (up 27.7% YoY) with H1 domestic at $16.0 million (up 32.5% YoY); international Q2 sales were $1.0 million (down 38.9% YoY) and H1 international $1.6 million (down 35.7% YoY).
3
Independent financial-health metrics from GuruFocus show ImmuCell with a GF Score of 55/100 and an Altman Z-score of 4.5, alongside a market capitalization around $103.5 million, suggesting a moderate overall performance with solid financial stability.
4
The company attributed gains in the quarter to targeted growth in year-round dairy customers and expanded commercial effort, with Dual-Force up 23.8% and Tri-Shield up 8.3% in that segment; the firm also provided details on a conference call and related access information for investors.
ImmuCell Corporation posted preliminary Q2 2026 product sales of $7.2 million, an 11.5% jump from the same period last year, according to MarketScreener. The Maine-based animal health company also reported first-half sales of $17.5 million, up 20.9% year over year — a strong mid-year showing for its cattle biologics business.
The gains were led by a surge in U.S. demand. Domestic sales climbed 27.7% to $6.2 million in the quarter. International sales, however, fell 38.9% to roughly $1.0 million, creating a split picture for the quarter, MarketScreener reported.
Tri-Shield and Dual-Force Lines Drive Domestic Momentum
ImmuCell's two main product lines both grew in Q2. The Tri-Shield First Defense line brought in $4.9 million for the quarter, up 8.3% year over year. The Dual-Force and other products line added $2.3 million, up 19.1%, according to MarketScreener.
Over the full first half, Tri-Shield reached $12.8 million in sales, a 25.1% increase. Dual-Force and other products hit $4.8 million, up 10.9%. The company said better product availability helped fuel the gains across both lines.
Year-Round Dairy Customers Fuel U.S. Sales Push
ImmuCell targeted year-round dairy customers — a more price-sensitive segment — to grow its domestic base. That strategy paid off. U.S. first-half sales reached $16.0 million, up 32.5% from the same period in 2025, Minichart reported.
An expanded sales team helped the company win new customers. Within the year-round dairy segment, Dual-Force grew 23.8% and Tri-Shield rose 8.3% for the quarter. Management remained cautious but optimistic about end-demand in Canada, even as international sales slid.
International Sales Slump After Distributor Restocking Headwinds
International revenue dropped sharply. Q2 international sales fell 38.9% to about $1.0 million. First-half international sales came in at $1.6 million, down 35.7% year over year, according to MarketScreener. Canada was the primary international market affected.
Management pointed to a difficult prior quarter caused by distributor restocking and backorders. Those headwinds made the international decline look steeper than underlying demand suggests. The company said it still sees solid end-demand in Canada and expects conditions to improve.
Financial Health and Upcoming Investor Call on August 14
Independent data from Minichart shows ImmuCell carries a market cap of around $103.5 million. Its Altman Z-score — a measure of financial stability — stands at 4.5, a level that signals low bankruptcy risk. Its overall GF Score is 55 out of 100, pointing to moderate business performance.
ImmuCell will hold a conference call on August 14, 2026 to discuss the full Q2 results. Seeking Alpha noted the preliminary figures are unaudited, meaning final numbers could shift slightly. Investors and analysts will watch for commentary on the international recovery and the commercial team's expansion plans.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
10
Articles
21
Reach
31
A
AnonymousAuthor
